134 related articles for article (PubMed ID: 24721727)
21. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
[TBL] [Abstract][Full Text] [Related]
23. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
[TBL] [Abstract][Full Text] [Related]
24. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
[TBL] [Abstract][Full Text] [Related]
25. DESIGN, SYNTHESIS, MOLECULAR DOCKING AND ANTI-BREAST CANCER ACTIVITY OF NOVEL QUINAZOLINONES TARGETING ESTROGEN RECEPTOR α.
Ahmed MF; Youns M; Belal A
Acta Pol Pharm; 2016; 73(1):115-27. PubMed ID: 27008806
[TBL] [Abstract][Full Text] [Related]
26. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation.
Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, and
Choudhari RC; Kaur K; Das A; Jaitak V
Curr Comput Aided Drug Des; 2024; 20(5):640-652. PubMed ID: 37888813
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
29. Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors.
El-Helby AA; Ayyad RRA; Sakr H; El-Adl K; Ali MM; Khedr F
Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29131379
[TBL] [Abstract][Full Text] [Related]
30. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
31. Design, Synthesis and Anti-breast Cancer Activity of Some Novel Substituted Isoxazoles as Anti-breast Cancer Agent.
Mokale SN; Sakle NS; Bhavale SA; Lokwani DK; Shelke VR
Anticancer Agents Med Chem; 2018; 18(7):1009-1015. PubMed ID: 29189180
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
[TBL] [Abstract][Full Text] [Related]
33. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking.
Xi L; Zhang JQ; Liu ZC; Zhang JH; Yan JF; Jin Y; Lin J
Org Biomol Chem; 2013 Jul; 11(26):4367-78. PubMed ID: 23715382
[TBL] [Abstract][Full Text] [Related]
34. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
[TBL] [Abstract][Full Text] [Related]
35. ZnO Nanoparticles Catalyst in the Synthesis of Bioactive Fused Pyrimidines as Anti-breast Cancer Agents Targeting VEGFR-2.
Dawood DH; Abbas EMH; Farghaly TA; Ali MM; Ibrahim MF
Med Chem; 2019; 15(3):277-286. PubMed ID: 30207239
[TBL] [Abstract][Full Text] [Related]
36. Novel multitarget inhibitors with antiangiogenic and immunomodulator properties.
Conesa-Milián L; Falomir E; Murga J; Carda M; Marco JA
Eur J Med Chem; 2019 May; 170():87-98. PubMed ID: 30878834
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in peptidomimetics antagonists targeting estrogen receptor α-coactivator interaction in cancer therapy.
Qin W; Xie M; Qin X; Fang Q; Yin F; Li Z
Bioorg Med Chem Lett; 2018 Sep; 28(17):2827-2836. PubMed ID: 30025900
[TBL] [Abstract][Full Text] [Related]
38. Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in vitro Biological Evaluation.
Zi M; Liu F; Wu D; Li K; Zhang D; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
ChemMedChem; 2019 Jul; 14(13):1291-1302. PubMed ID: 31131561
[TBL] [Abstract][Full Text] [Related]
39. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
40. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells.
Caruso JA; Campana R; Wei C; Su CH; Hanks AM; Bornmann WG; Keyomarsi K
Cell Cycle; 2014; 13(16):2587-99. PubMed ID: 25486199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]